Discovery and characterization of endogenous cannabinoids

被引:150
作者
Martin, BR
Mechoulam, R
Razdan, RK
机构
[1] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA
[2] Hebrew Univ Jerusalem, Jerusalem, Israel
[3] Organix Inc, Woburn, MA USA
关键词
anandamide; cannabinoids; structure-activity relationship; pharmacology;
D O I
10.1016/S0024-3205(99)00281-7
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The characterization of cannabinoid receptors and signal transduction mechanisms provided the impetus for the searching for endogenous ligands for this system. The result was a family of fatty acid derivatives that interact with cannabinoid receptors to varying degrees. The two ligands that have received the most attention are anandamide (AN) and 2-arachidonoly-glycerol (Ara-Gl). They are both present in central as well as peripheral tissues. Mechanisms for the synthesis and metabolism of AN have been described. Presently, the physiological stimuli for production and release of AN are unknown. As a result, elucidation of its physiological role remains elusive. However, it seems reasonable to conclude that both AN and 2-Ara-Gl interact with cannabinoid receptors in both peripheral and central tissue to produce a wide range of effects. Administration of these ligands to laboratory animals produce effects that are quite similar to those elicited by Delta(9)-tetrahydrocannabinol (THC), the psychoactive constituent in marijuana. Nevertheless, there are some pharmacological differences between the plant-derived THC and the endogenous cannabinoids that could be due to either pharmadynamic or pharmacokinetics dissimilarities. Extensive structure-activity relationship studies have provided some vital insights into the actions of the endogenous ligands. First and foremost, systematic structural alterations in AN have additional support that it is acting at the cannabinoid receptors in a fashion similar to that of THC. Development of metabolically stable analogs of AN, as well as those with greater receptor affinity, have helped substantiate AN and THC similarities. Nevertheless, pharmacological differences remain between the endogenous and exogenous ligands. Whether these differences are due to the nature of their interaction with the cannabinoid receptors, activation of unique signaling pathways, interactions with non-cannabinoid receptors, or pharmacokinetic considerations remain to be resolved.
引用
收藏
页码:573 / 595
页数:23
相关论文
共 111 条
[1]   (R)-METHANANDAMIDE - A CHIRAL NOVEL ANANDAMIDE POSSESSING HIGHER POTENCY AND METABOLIC STABILITY [J].
ABADJI, V ;
LIN, SY ;
TAHA, G ;
GRIFFIN, G ;
STEVENSON, LA ;
PERTWEE, RG ;
MAKRIYANNIS, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (12) :1889-1893
[2]  
Aceto MD, 1998, J PHARMACOL EXP THER, V287, P598
[3]   CANNABINOID PRECIPITATED WITHDRAWAL BY THE SELECTIVE CANNABINOID RECEPTOR ANTAGONIST, SR 141716A [J].
ACETO, MD ;
SCATES, SM ;
LOWE, JA ;
MARTIN, BR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 282 (1-3) :R1-R2
[4]  
ADAMS IB, 1995, J PHARMACOL EXP THER, V273, P1172
[5]  
Adams IB, 1998, J PHARMACOL EXP THER, V284, P1209
[6]   PHARMACOLOGICAL AND BEHAVIORAL-EVALUATION OF ALKYLATED ANANDAMIDE ANALOGS [J].
ADAMS, IB ;
RYAN, W ;
SINGER, M ;
RAZDAN, RK ;
COMPTON, DR ;
MARTIN, BR .
LIFE SCIENCES, 1995, 56 (23-24) :2041-2048
[7]  
[Anonymous], CANNABINOID RECEPTOR
[8]   The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condensation of arachidonic acid and ethanolamine [J].
Arreaza, G ;
Devane, WA ;
Omeir, RL ;
Sajnani, G ;
Kunz, J ;
Cravatt, BF ;
Deutsch, DG .
NEUROSCIENCE LETTERS, 1997, 234 (01) :59-62
[9]  
BACHUR NR, 1966, J BIOL CHEM, V241, P1308
[10]   DELTA-9-TETRAHYDROCANNABINOL DISCRIMINATION IN RATS AS A MODEL FOR CANNABIS INTOXICATION [J].
BALSTER, RL ;
PRESCOTT, WR .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1992, 16 (01) :55-62